Publications by authors named "W Gomm"
Background: The SARS-CoV-2 pandemic was a challenge for health care systems worldwide. People with pre-existing chronic diseases have been identified as vulnerable patient groups. Furthermore, some of the drugs used for these chronic diseases such as antihypertensive drugs have been discussed as possible influencing factors on the progression of COVID-19.
View Article and Find Full Text PDFBackground: N-Nitrosodimethylamine (NDMA), classified as a probable human carcinogen, has been found as a contaminant in the antihypertensive drug valsartan. Potentially carcinogenic effects associated with the consumption of NDMAcontaminated valsartan have not yet been analyzed in large-scale cohort studies. We therefore carried out the study reported here to explore the association between NDMA-contaminated valsartan and the risk of cancer.
View Article and Find Full Text PDFArticle Synopsis
- Pre-emptive pharmacogenetic testing can help prevent adverse drug reactions and therapy resistance, but it's not commonly used in Germany due to insufficient clinical and economic evidence.
- The EMPAR study will analyze the impact of pharmacogenetic profiles on healthcare service usage by examining data from around 10,000 patients, focusing on those prescribed anticoagulants and cholesterol-lowering drugs.
- The study will look into healthcare utilization, work incapacity rates, and treatment costs to determine the benefits and cost-effectiveness of routine pharmacogenetic testing in the German healthcare system.
Background: Recent evidence indicates an important role for neuroinflammation in the pathological cascade of Alzheimer's disease (AD), and neuroinflammation is increasingly being recognized as a potential therapeutic target.
Objective: To assess the impact of glucocorticoids on the risk of developing dementia.
Methods: We used health insurance data of the largest German health insurer from 2004-2013 with a baseline sample of 176,485 persons aged 50 years and older to study the association of glucocorticoid treatment and incidence of dementia.
Background: There is evidence that uric acid may have antioxidant and neuroprotective effects and might therefore alter the risk for neurodegenerative diseases such as dementia. So far, the relation between serum uric acid (SUA) levels or hyperuricemia and dementia remains elusive. Most studies focused on the disease or SUA levels.
View Article and Find Full Text PDF